Management of bacterial meningitis
Reading File
Finding Sources
Searching PubMed
"bacterial meningitis"[MeSH Terms] AND "management"[tiab]
Searching the Web
bacterial meningitis management guidelines 2024 2025
Finding Sources
Searching PubMed
"bacterial meningitis" AND treatment
Reading Web Page
https://reference.medscape.com/cc2/p10/who-meningitis-guidan…
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
I now have comprehensive data from multiple authoritative textbooks. Let me compile the full management guide.
Management of Bacterial Meningitis
Bacterial meningitis is a neurologic emergency with mortality ~15% even with treatment. Outcome depends critically on speed of diagnosis and initiation of therapy.
1. Initial Assessment & Diagnosis
Clinical Presentation
The classic triad — fever, headache, nuchal rigidity — is present in ~85% of adult patients. Additional features include:
- Photophobia, phonophobia, nausea/vomiting
- Altered consciousness (~30%), seizures (~30%)
- Cranial nerve palsies and focal deficits (10–20%)
- Kernig sign (resistance to knee extension with hip at 90°) and Brudzinski sign (involuntary knee flexion on passive neck flexion): low sensitivity (<12%) but high specificity
- Petechial/purpuric rash on extremities → strongly suggests N. meningitidis
- Shock + purpura + DIC → Waterhouse-Friderichsen syndrome (bilateral adrenal hemorrhage in meningococcemia)
Special populations:
- Neonates: poor feeding, irritability, temperature instability, bulging fontanelle, seizures; nuchal rigidity unreliable <1 year
- Elderly: insidious onset, variable meningeal signs, altered mental status without fever
- Immunocompromised: altered mental status may be the only finding
When to Obtain CT Before LP
Perform CT head first if the patient has:
- Papilledema
- New-onset seizures
- Focal neurologic deficits
- Decreased level of consciousness
- → If CT is needed, draw blood cultures and start antibiotics immediately — do not delay treatment for imaging
CSF Findings
| Parameter | Bacterial Meningitis | Viral Meningitis |
|---|---|---|
| Opening pressure (mmH₂O) | >180 | Normal or elevated |
| WBC (cells/mm³) | 1,000–10,000 (median 1,195) | <300 |
| Neutrophils | >80% | <20% |
| Glucose (mg/dL) | <40 (or <40% serum glucose) | >40 |
| Protein (mg/dL) | 100–500 | Normal or slightly elevated |
| Gram stain positive | 60–90% | Negative |
| Culture positive | 70–85% | ~50% |
— Textbook of Family Medicine 9e; ROSEN's Emergency Medicine
2. Common Pathogens by Age
| Age | Predominant Pathogens |
|---|---|
| 0–1 month | Group B streptococcus, E. coli, Listeria monocytogenes, S. pneumoniae |
| 1–3 months | Group B strep, Listeria, S. pneumoniae, N. meningitidis, H. influenzae |
| 3 months–18 years | S. pneumoniae, N. meningitidis, H. influenzae |
| 18–50 years | S. pneumoniae, N. meningitidis |
| >50 years | S. pneumoniae (~70%), Listeria, gram-negative bacilli |
| Post-neurosurgery/trauma | Coagulase-negative staphylococci, S. aureus, Cutibacterium acnes, Pseudomonas aeruginosa |
— Textbook of Family Medicine 9e; Goldman-Cecil Medicine
3. Empirical Antibiotic Therapy
Start within 1 hour of clinical suspicion. Never delay antibiotics to wait for LP results if CT is required.
Standard Empirical Regimen (Community-Acquired Adults)
| Component | Drug | Dose |
|---|---|---|
| Coverage for pneumococcus (resistant strains) | Vancomycin | 15–20 mg/kg IV q8h |
| Coverage for gram-negatives & pneumococcus | Ceftriaxone | 2 g IV q12h |
| (or) | Cefotaxime | 3 g IV q6h |
Add ampicillin 2 g IV q4h when Listeria coverage is needed:
- Adults >50 years
- Immunocompromised, pregnant, alcoholic, diabetic
- Signs of brainstem involvement
- Gram-positive rods on CSF Gram stain
Consider gentamicin (synergistically with ampicillin) in confirmed/suspected Listeria meningitis — use cautiously if renal impairment.
Neonates
- Cefotaxime (not ceftriaxone — displaces bilirubin from albumin in hyperbilirubinemia) + ampicillin
- Ampicillin: 100 mg/kg/dose q8h (days 0–7); 75 mg/kg/dose (days 8–28)
Healthcare-Associated / Post-Neurosurgical Meningitis
- Cefepime 2 g IV q8h (instead of ceftriaxone) + vancomycin
- Covers resistant organisms including Pseudomonas
- For P. aeruginosa: ceftazidime or cefepime; alternatives include aztreonam, ciprofloxacin, meropenem ± aminoglycoside
Allergy / Resistant Strains
- Cephalosporin allergy: meropenem or chloramphenicol
- Highly penicillin/cephalosporin-resistant pneumococcus: vancomycin + rifampin IV; or linezolid 600 mg q12h + vancomycin; or moxifloxacin 400 mg OD + vancomycin
— ROSEN's Emergency Medicine; Textbook of Family Medicine 9e; Goldman-Cecil Medicine
4. Targeted Therapy by Organism (After Culture/Sensitivity)
| Organism | First-Line | Alternatives |
|---|---|---|
| S. pneumoniae (susceptible) | Ceftriaxone or cefotaxime | Meropenem, fluoroquinolone |
| S. pneumoniae (resistant) | Vancomycin + ceftriaxone | Vancomycin + rifampin, linezolid |
| N. meningitidis | 3rd-generation cephalosporin | Penicillin G, ampicillin, chloramphenicol, fluoroquinolone |
| L. monocytogenes | Ampicillin (± gentamicin) | TMP-SMX, meropenem |
| H. influenzae | 3rd-generation cephalosporin | Chloramphenicol, cefepime, meropenem, fluoroquinolone |
| E. coli / gram-negative bacilli | 3rd-generation cephalosporin | Cefepime, meropenem, aztreonam, fluoroquinolone |
| S. agalactiae (Group B) | Ampicillin or penicillin G | 3rd-generation cephalosporin |
— Textbook of Family Medicine 9e
5. Adjunctive Corticosteroid Therapy
Dexamethasone is a critical adjunct in adult bacterial meningitis.
- Dose: 0.15 mg/kg (up to 10 mg) IV q6h × 4 days
- Timing: Administer with or 20 minutes BEFORE the first antibiotic dose for maximum efficacy
- Benefit:
- Reduces mortality in pneumococcal meningitis
- Reduces hearing loss in H. influenzae meningitis
- Benefit is mainly demonstrated in high-income countries (better access to specialist care)
- Caution: May reduce CSF vancomycin penetration (if given with vancomycin for resistant pneumococcus, consider rifampin addition)
- Discontinue if Listeria meningitis is confirmed — steroids increase adverse outcomes in Listeria CNS infection
- No role for empiric corticosteroids in neonatal meningitis
— ROSEN's Emergency Medicine; Goldman-Cecil Medicine
6. Supportive & ICU Management
Fluid Management
- Give normal daily fluid requirements + volume deficit correction
- Avoid excessive fluid — can worsen cerebral edema and herniation
- Restrict fluid if SIADH (hyponatremia) develops; monitor serum sodium closely
Raised Intracranial Pressure (ICP)
- Head of bed elevation (30°)
- Endotracheal intubation if severely elevated ICP
- Mannitol or hypertonic saline (osmotherapy)
- Maintain eucapnia on ventilator (avoid aggressive hyperventilation except as bridge)
- Avoid hypotension and hypoxia
Seizure Control
- Prompt treatment with benzodiazepines (first-line), phenytoin, or levetiracetam
- Particularly important in neonates (seizures in 40%)
Monitoring
- Neurological observations (GCS, pupils, focal signs)
- Watch for cerebral venous thrombosis (~1% of cases): presents with new seizures, focal deficits, altered sensorium
- Coagulation screen (PT, PTT, platelets) for DIC in severe meningococcemia
7. Duration of Antibiotic Therapy
| Organism | Duration |
|---|---|
| N. meningitidis | 5–7 days |
| H. influenzae | 7 days |
| S. pneumoniae | 10–14 days |
| Listeria monocytogenes | 21 days |
| Gram-negative bacilli (including E. coli) | 21 days |
| Healthcare-associated / Pseudomonas | ≥3 weeks (or 2 weeks after first sterile CSF culture) |
8. Chemoprophylaxis for Close Contacts
Meningococcal meningitis: ciprofloxacin 500 mg PO single dose (adults) or rifampin 600 mg PO q12h × 2 days → for household contacts, healthcare workers with unprotected mucosal exposure.
Group B streptococcus (neonatal prevention): intrapartum IV penicillin G (or ampicillin) for colonized mothers — highly effective for early-onset disease.
9. Complications
| Complication | Notes |
|---|---|
| Hearing loss | Most common in H. influenzae and pneumococcal meningitis; reduced by dexamethasone |
| Hydrocephalus | Due to CSF outflow obstruction; may require surgical drainage |
| Cerebral infarction | From vasculitis/venous thrombosis; assess with MRI |
| Waterhouse-Friderichsen syndrome | Bilateral adrenal hemorrhage in meningococcemia; DIC, cardiovascular collapse |
| Subdural empyema | Requires neurosurgical drainage |
| Residual neurologic deficits | Highest in pneumococcal meningitis |
10. Key Recent Evidence (PubMed, 2023–2026)
- Bulaeva & Derber, Med Clin North Am 2025 (PMID 40185548): Contemporary review reinforcing standard management framework
- Xu et al., Virulence 2024 (PMID 39192572): Advances in pathogenesis and treatment of pneumococcal meningitis, including emerging targets for adjunctive therapy
- WHO Guidelines on Meningitis 2025 (published April 2025): Reaffirms ceftriaxone/cefotaxime as universal empiric backbone; antibiotics must be started within 1 hour of suspicion
⚠️ Note: WHO 2025 guidelines are the most current international standard. For TB meningitis, a separate 4-drug RHEZ regimen applies (isoniazid + rifampin + pyrazinamide + ethambutol).
Sources: ROSEN's Emergency Medicine (9e), Goldman-Cecil Medicine, Textbook of Family Medicine (9e), Bradley & Daroff's Neurology in Clinical Practice, WHO Meningitis Guidelines 2025.
This is a shared conversation. Sign in to Orris to start your own chat.